Gotham Asset Management LLC Has $2.57 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gotham Asset Management LLC trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 37.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,924 shares of the biopharmaceutical company’s stock after selling 6,651 shares during the quarter. Gotham Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $2,571,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Focus Partners Wealth grew its stake in Alnylam Pharmaceuticals by 245.1% during the fourth quarter. Focus Partners Wealth now owns 4,427 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 3,144 shares during the last quarter. Ethic Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 22.9% during the fourth quarter. Ethic Inc. now owns 4,886 shares of the biopharmaceutical company’s stock worth $1,150,000 after purchasing an additional 910 shares during the last quarter. FORA Capital LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $2,988,000. Driehaus Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.5% during the fourth quarter. Driehaus Capital Management LLC now owns 33,480 shares of the biopharmaceutical company’s stock worth $7,878,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $35,000. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ALNY shares. Royal Bank of Canada increased their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday, March 21st. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a report on Friday, March 21st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. HC Wainwright reiterated a “buy” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, Chardan Capital raised their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $319.17.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,017,271.63. The trade was a 11.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Up 5.9%

NASDAQ ALNY opened at $283.40 on Friday. The firm has a market cap of $36.95 billion, a P/E ratio of -130.60 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock’s 50-day moving average is $252.80 and its 200-day moving average is $253.76. Alnylam Pharmaceuticals, Inc. has a one year low of $144.73 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.16) earnings per share. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.